183 related articles for article (PubMed ID: 25070547)
1. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Edelman AB; Cherala G; Munar MY; McInnis M; Stanczyk FZ; Jensen JT
Contraception; 2014 Nov; 90(5):550-6. PubMed ID: 25070547
[TBL] [Abstract][Full Text] [Related]
2. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.
Edelman AB; Cherala G; Munar MY; Dubois B; McInnis M; Stanczyk FZ; Jensen JT
Contraception; 2013 Feb; 87(2):220-6. PubMed ID: 23153898
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
5. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti CE; O'Leary CM; Hendy CH; Waters DH; Margolis MB
Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
Kuhnz W; al-Yacoub G; Fuhrmeister A
Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
[TBL] [Abstract][Full Text] [Related]
8. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Taekema-Roelvink ME; Swart PJ; Kuipers ME; Krauwinkel WJ; Visser N; Smulders RA
Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.
Westhoff CL; Torgal AH; Mayeda ER; Pike MC; Stanczyk FZ
Contraception; 2010 Jun; 81(6):474-80. PubMed ID: 20472113
[TBL] [Abstract][Full Text] [Related]
11. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.
Edelman AB; Carlson NE; Cherala G; Munar MY; Stouffer RL; Cameron JL; Stanczyk FZ; Jensen JT
Contraception; 2009 Aug; 80(2):119-27. PubMed ID: 19631786
[TBL] [Abstract][Full Text] [Related]
12. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
13. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
[TBL] [Abstract][Full Text] [Related]
14. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
Rosenfeld WE; Doose DR; Walker SA; Nayak RK
Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
16. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
Archer DF; Timmer CJ; Lammers P
Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
[TBL] [Abstract][Full Text] [Related]
18. Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.
Barcellos T; Natavio M; Stanczyk FZ; Luo D; Jusko WJ; Bender NM
Contraception; 2019 Oct; 100(4):283-287. PubMed ID: 31194965
[TBL] [Abstract][Full Text] [Related]
19. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
[TBL] [Abstract][Full Text] [Related]
20. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Young A; Anzures-Cabrera J; Derks M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
